US FDA approves Amneal's migraine treatment
15/05/2025 13:09
May 15 (Reuters) - Amneal Pharmaceuticals AMRX.O said on Thursday the U.S. Food and Drug Administration has approved its self-administered migraine drug. (Reporting by Mariam Sunny in Bengaluru; Editing by Devika Syamnath) ((Mariam.ESunny@thomsonreuters.com;))
Recent news on Amneal Pharmaceuticals
See all newsUS RESEARCH ROUNDUP-3M Company, Constellation Energy, Metropolitan Bank Holding
US FDA is working with manufacturers to boost estrogen patch supply amid access concerns (updated)
U.S. RESEARCH ROUNDUP- Intuit, MongoDB, Zscaler
U.S. STOCKS ON THE MOVE-Mastercard, Yum, Equinix
Amneal Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary